Education
About Us
Working with TipRanks
Follow Us
4D Molecular Therapeutics (FDMT)
NASDAQ:FDMT
FDMT Stock Chart & Stats
$8.69
-$0.14(-2.20%)
At close: 4:00 PM EST
$8.69
-$0.14(-2.20%)
Day’s Range― - ―
52-Week Range$2.24 - $12.34
Previous CloseN/A
Volume165.32K
Average Volume (3M)841.91K
Market Cap
$526.21M
Enterprise Value$204.94M
Total Cash (Recent Filing)$305.06M
Total Debt (Recent Filing)$22.26M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Feb 27, 2026EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.01
Shares Outstanding57,135,075
10 Day Avg. Volume772,291
30 Day Avg. Volume841,914
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)0.59
Price to Sales (P/S)8120.72
P/FCF Ratio-2.17
Enterprise Value/Market Cap0.39
Enterprise Value/Revenue1.71K
Enterprise Value/Gross Profit-2.12
Enterprise Value/Ebitda-0.90
Forecast
1Y Price Target
$33.83Price Target Upside289.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-3.26
Revenue Forecast (FY)$33.52M
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessPositive interim Phase 1 data from the ongoing Phase 1/2 AEROW trial of aerosolized gene therapy candidate 4D-710 in cystic fibrosis patients was announced.
Financial Strength$100mn financing strengthens the balance sheet, supporting the advancement of phase 3 trials and the initiation of the pivotal program in DME.
Strategic PartnershipsThe company entered a strategic partnership with Otsuka Pharmaceutical for 4D-150 development and commercialization in the APAC region, resulting in $85M upfront cash and expectations of at least $50M in cost sharing, broadening the potential global footprint.
Bears Say
Clinical Trial ChallengesHigher doses of 4D-710 resulted in transgene expression above target levels and were associated with expression in undesirable cell types.
4D Molecular Therapeutics News
FDMT FAQ
What was 4D Molecular Therapeutics’s price range in the past 12 months?
4D Molecular Therapeutics lowest stock price was $2.23 and its highest was $12.34 in the past 12 months.
What is 4D Molecular Therapeutics’s market cap?
4D Molecular Therapeutics’s market cap is $526.21M.
When is 4D Molecular Therapeutics’s upcoming earnings report date?
4D Molecular Therapeutics’s upcoming earnings report date is Feb 27, 2026 which is in 69 days.
How were 4D Molecular Therapeutics’s earnings last quarter?
4D Molecular Therapeutics released its earnings results on Nov 10, 2025. The company reported -$1.01 earnings per share for the quarter, missing the consensus estimate of -$0.983 by -$0.027.
Is 4D Molecular Therapeutics overvalued?
According to Wall Street analysts 4D Molecular Therapeutics’s price is currently Undervalued.
Does 4D Molecular Therapeutics pay dividends?
4D Molecular Therapeutics does not currently pay dividends.
What is 4D Molecular Therapeutics’s EPS estimate?
4D Molecular Therapeutics’s EPS estimate is -0.53.
How many shares outstanding does 4D Molecular Therapeutics have?
4D Molecular Therapeutics has 57,135,075 shares outstanding.
What happened to 4D Molecular Therapeutics’s price movement after its last earnings report?
4D Molecular Therapeutics reported an EPS of -$1.01 in its last earnings report, missing expectations of -$0.983. Following the earnings report the stock price went down -3.143%.
Which hedge fund is a major shareholder of 4D Molecular Therapeutics?
Currently, no hedge funds are holding shares in FDMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
4D Molecular Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.83 (289.30% Upside)
$33.83 (289.30% Upside)
Blogger Sentiment
Bullish
FDMT Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 4.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $32.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.72%
12-Months-Change
Fundamentals
Return on Equity
-45.38%
Trailing 12-Months
Asset Growth
-29.81%
Trailing 12-Months
Company Description
4D Molecular Therapeutics
4D Molecular Therapeutics (FDMT) is a biotechnology company focused on developing innovative gene therapies for the treatment of genetically defined diseases. Utilizing its proprietary 4D platform, the company designs and optimizes adeno-associated virus (AAV) vectors that can deliver therapeutic genes effectively to target tissues. FDMT operates primarily in the sectors of gene therapy and molecular medicine, and its core products revolve around its advanced AAV therapies aimed at addressing unmet medical needs in various genetic disorders.
FDMT Stock 12 Month Forecast
Average Price Target
$33.83
▲(289.30% Upside)
Technical Analysis
Assembly Biosciences
―
Korro Bio
―
Design Therapeutics
―
Immuneering
―
Aura Biosciences Inc
―
Ownership Overview
2.12% Insiders
11.77% Mutual Funds
26.31% Other Institutional Investors
49.06% Public Companies and Individual Investors